GlaxoSmithKline plc (LON:GSK) has been given a consensus rating of “Hold” by the twenty-three ratings firms that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is GBX 1,551.90 ($21.44).
A number of equities research analysts have commented on GSK shares. Deutsche Bank raised their price objective on GlaxoSmithKline from GBX 1,380 ($19.07) to GBX 1,440 ($19.89) and gave the stock a “hold” rating in a research report on Thursday, January 11th. set a GBX 1,925 ($26.60) price objective on GlaxoSmithKline and gave the stock a “buy” rating in a research report on Thursday, October 26th. Morgan Stanley decreased their price objective on GlaxoSmithKline from GBX 1,450 ($20.03) to GBX 1,400 ($19.34) and set an “underweight” rating for the company in a research report on Friday, December 1st. Beaufort Securities upgraded GlaxoSmithKline to a “buy” rating and raised their price objective for the stock from GBX 1,450 ($20.03) to GBX 1,500 ($20.72) in a research report on Thursday, February 8th. Finally, Berenberg Bank reduced their price target on GlaxoSmithKline from GBX 1,835 ($25.35) to GBX 1,760 ($24.32) and set a “buy” rating for the company in a report on Thursday, November 2nd.
In related news, insider Sir Roy Anderson acquired 562 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were acquired at an average cost of GBX 1,278 ($17.66) per share, with a total value of £7,182.36 ($9,923.13). Also, insider Patrick Vallance sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.10), for a total value of £262,000 ($361,978.45). Insiders purchased a total of 590 shares of company stock worth $754,966 over the last three months.
The business also recently disclosed a dividend, which will be paid on Thursday, April 12th. Investors of record on Thursday, February 22nd will be paid a GBX 23 ($0.32) dividend. This represents a dividend yield of 1.78%. This is an increase from GlaxoSmithKline’s previous dividend of $19.00. The ex-dividend date is Thursday, February 22nd.
COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline plc (GSK) Receives Average Rating of “Hold” from Analysts” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/02/19/glaxosmithkline-plc-gsk-receives-average-rating-of-hold-from-analysts.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.